Table 3 Tumor response by RET fusion status
|
RET+ cohort (N = 46) | RET- cohort (N = 5761) | p-value* | |
|---|---|---|---|
| Any first-line therapy, unadjusted | n (%)a | n (%)a | |
| Complete response (CR) | 1 (3.7) | 112 (4.7) | 0.17 |
| Partial response (PR) | 20 (74.1) | 1284 (53.9) | |
| Stable disease (SD) | 2 (7.4) | 530 (22.3) | |
| Progressive Disease (PD) | 4 (14.8) | 455 (19.1) | |
| Missing/unknown | 19 | 3380 | |
| First-line pembro + PC (KN-189 regimen), unadjusted | N = 9 | N = 665 | |
| CR | 1 (12.5) | 15 (3.4) | 0.15 |
| PR | 5 (62.5) | 249 (57.1) | |
| SD | 0 (0.0) | 100 (22.9) | |
| PD | 2 (25.0) | 72 (16.5) | |
| Missing/unknown | 1 | 229 | |
| Any second-line therapy, unadjusted | N = 23 | N = 3173 | |
| CR | 0 (0.0) | 47 (2.9) | 0.93 |
| PR | 6 (42.9) | 564 (35.1) | |
| SD | 4 (28.6) | 478 (29.7) | |
| PD | 4 (28.6) | 519 (32.3) | |
| Missing/unknown | 9 | 1565 | |
| Objective response rate (ORR) | Odds ratio (95% confidence interval) | p-value | |
| First line, unadjusted, n = 2408 | 2.47 (0.99, 6.14) | 0.05 | |
| First-line pembro +PC , unadjusted, n = 444 | 1.95 (0.39, 9.80) | 0.49 | |
| First line, adjustedb, n = 2408 | 0.44 (0.17, 1.13) | 0.09 | |
| First line pembro + PC, adjustedb, n = 444 | 0.63 (0.10, 3.84) | 0.61 | |
| Second line, unadjusted, n = 1622 | 1.22 (0.42, 3.54) | 0.78 | |
| Second line, adjustedb, n = 1622 | 0.58 (0.18, 1.87) | 0.36 | |
